-
支气管肺发育不良(bronchopulmonary dysplasia,BPD)常见于早产儿,属于慢性呼吸系统疾病。有数据统计,BPD在胎龄 < 28周的早产儿中的发病率超过50%,重度BPD患儿的病死率达到64%,存活的患儿神经系统发育障碍的发生率是正常新生儿的2~3倍,是一种严重影响早产儿生命健康的疾病[1-3]。至今BPD尚无特效治疗方法,虽然糖皮质激素对BPD的治疗有一定的效果,但是激素存在抑制患儿神经系统发育等不良反应,目前在临床上的应用存在较大争议。孟鲁司特钠(montelukast,MK)是一种半胱氨酰白三烯受体拮抗剂,属于非激素类抗炎药,对多种疾病具有抗炎、调节免疫的防护作用,且不良反应较少。目前,有研究[4-5]显示出MK治疗BPD的有效性和安全性,但其抑制BPD发展的确切机制尚不清楚。因此,本研究旨在探讨MK对BPD大鼠免疫因子的影响以及细胞因子水平的调节作用。
-
大鼠Ri、Re水平BPD组高于MK组,MK组高于对照组(P<0.05),Cl、MVV、FEV1/FVC水平BPD组低于MK组,MK组低于对照组(P<0.05)(见表 1)。
分组 n Ri/(cmH2O·L-1·S-1) Re/(cmH2O·L-1·S-1) Cl/(mL/ cmH2O) MVV/mL (FEV1/FVC)/% MK组 20 4.52±0.97 3.44±0.82 73.81±25.26 8.29±2.37 55.27±15.30 BPD组 20 7.21±1.36* 6.41±0.96* 54.22±13.19* 4.53±1.26* 42.51±12.99* 对照组 20 3.55±0.84*△ 2.94±0.77*△ 80.77±23.50*△ 9.77±2.52*△ 67.28±16.33*△ F — 61.71 96.54 8.33 32.30 13.75 P — <0.01 <0.01 <0.01 <0.01 <0.01 MS组内 — 1.165 18.176 454.765 4.518 223.166 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 1 3组大鼠肺功能比较(x±s)
-
大鼠Th1、Th1/ Th2水平BPD组高于MK组,MK组高于对照组(P<0.05),Th2水平BPD组低于MK组,MK组低于对照组(P<0.05)(见表 2)。
分组 n Th1/% Th2/% Th1/ Th2 MK组 20 7.21±2.94 6.31±0.94 1.52±0.86 BPD组 20 12.57±4.06* 3.41±1.06* 4.33±2.70* 对照组 20 5.62±2.33*△ 7.51±1.49*△ 0.93±0.27*△ F — 26.04 63.07 24.44 P — <0.01 <0.01 <0.01 MS组内 — 10.185 1.409 2.701 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 2 3组大鼠Th1、Th2细胞水平比较(x±s)
-
大鼠IFN-γ、TNF-α、IL-1β、IL-6水平BPD组高于MK组,MK组高于对照组(P<0.05)(见表 3)。
分组 n IFN-γ/(μg/L) TNF-α/(ng/mL) IL-1β/(pg/mL) IL-6/(pg/mL) MK组 20 52.19±7.26 3.18±1.07 137.42±9.55 184.31±27.68 BPD组 20 64.22±6.33* 7.44±2.46* 177.86±12.31* 238.69±43.15* 对照组 20 44.18±8.39*△ 1.31±0.29*△ 91.42±4.92*△ 137.42±27.66*△ F — 37.41 81.34 420.43 45.42 P — <0.01 <0.01 <0.01 <0.01 MS组内 — 54.390 2.427 88.982 1131.060 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 3 3组大鼠局部肺组织促炎因子相关细胞因子水平比较(x±s)
-
大鼠IL-4、IL-10、IL-13水平BPD组高于MK组,MK组高于对照组(P<0.05)(见表 4)。
分组 n IL-4/(pg/mL) IL-10/(ng/mL) IL-13/(ng/L) MK组 20 94.22±16.37 52.16±9.42 42.33±9.16 BPD组 20 115.67±15.23* 77.86±10.49* 63.47±12.29* 对照组 20 72.15±9.88*△ 38.44±5.29*△ 14.31±5.22*△ F — 47.55 105.96 139.16 P — <0.01 <0.01 <0.01 MS组内 — 199.181 75.587 87.399 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 4 3组大鼠局部肺组织抗炎因子相关细胞因子水平比较(x±s)
孟鲁司特钠对支气管肺发育不良大鼠Th1Th2细胞平衡及其相关细胞因子水平的调节作用
Regulating effects of montelukast sodium on Th1Th2 cells balance and related cytokines levels in rats with bronchopulmonary dysplasia
-
摘要:
目的观察孟鲁司特钠(MK)对支气管肺发育不良(BPD)大鼠Th1Th2细胞平衡及其相关细胞因子水平的调节作用。 方法随机选择SPF级健康SD孕3周左右,体质量在200~250 g孕鼠60只进行实验,将60只孕3周左右自然分娩SD母鼠与新生大鼠分为3组,每组20只,分别为:MK处理BPD模型组(MK组)、BPD模型组(BPD组)、常氧饲养对照组(对照组)。MK组、BPD组饲养在95%的高氧环境中,其中MK组给予MK(腹腔注射,10 mg·kg-1·d-1)处理,BPD组给予等剂量0.9%氯化钠溶液处理。对照组亦给予等剂量0.9%氯化钠溶液处理,饲养在常氧环境中。比较3组大鼠的肺功能、肺损伤局部巨噬细胞亚群和Th细胞功能亚群、肺损伤局部促炎和抗炎细胞因子水平。 结果大鼠Ri、Re、Th1、Th1/Th2、IFN-γ、TNF-α、IL-1β、IL-6、IL-4、IL-10、IL-13水平BPD组高于MK组,MK组高于对照组(P < 0.05);Cl、MVV、FEV1/FVC、Th2水平BPD组低于MK组,MK组低于对照组(P < 0.05)。 结论MK具有调节支气管肺发育不良大鼠Th1、Th2细胞平衡,降低相关细胞因子水平,改善肺功能的作用。 Abstract:ObjectiveTo observe the regulating effects of montelukast sodium (MK) on the balance of Th1Th2 cells and levels of related cytokines in rats with bronchopulmonary dysplasia (BPD). MethodsSixty healthy SPF SD rats, 3 weeks of gestation and weighing 200-250g, were randomly selected for the experiment, and 60 natural born SD rats and newborn rats were divided into the BPD model treated with MK group (MK group), BPD model group (BPD group) and normoxia feeding control group (control group) (20 rats in each group), respectively.The MK group and BPD group were fed in 95% hyperoxia environment, the MK group was intraperitoneally injected with 10mg·kg-1·d-1 of MK, and the BPD group was injected with the same volume of 0.9% sodium chloride solution.The control group was injected with the same volume of 0.9% sodium chloride solution, and fed in the normoxic environment.The lung function, macrophage subsets, Th cell subsets and levels of pro-inflammatory and anti-inflammatory cytokines were compared among three groups. ResultsThe levels of Ri, Re, Th1, Th1/Th2, IFN-γ, TNF-α, IL-1β, IL-6, IL-4, IL-10 and IL-13 in BPD group were higher than those in MK group and those in MK group were higher than those in control group (P < 0.05).The levels of Cl, MVV, FEV1/FVC, Th2 in BPD group were lower than those in MK group, and those in MK group were lower than those in control group (P < 0.05). ConclusionsMK can regulate the balance of Th1Th2 cells, and reduce the levels of related cytokines in rats with BPD. -
Key words:
- montelukast sodium /
- bronchopulmonary dysplasia /
- Th cells functional subgroup /
- rat
-
表 1 3组大鼠肺功能比较(x±s)
分组 n Ri/(cmH2O·L-1·S-1) Re/(cmH2O·L-1·S-1) Cl/(mL/ cmH2O) MVV/mL (FEV1/FVC)/% MK组 20 4.52±0.97 3.44±0.82 73.81±25.26 8.29±2.37 55.27±15.30 BPD组 20 7.21±1.36* 6.41±0.96* 54.22±13.19* 4.53±1.26* 42.51±12.99* 对照组 20 3.55±0.84*△ 2.94±0.77*△ 80.77±23.50*△ 9.77±2.52*△ 67.28±16.33*△ F — 61.71 96.54 8.33 32.30 13.75 P — <0.01 <0.01 <0.01 <0.01 <0.01 MS组内 — 1.165 18.176 454.765 4.518 223.166 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 2 3组大鼠Th1、Th2细胞水平比较(x±s)
分组 n Th1/% Th2/% Th1/ Th2 MK组 20 7.21±2.94 6.31±0.94 1.52±0.86 BPD组 20 12.57±4.06* 3.41±1.06* 4.33±2.70* 对照组 20 5.62±2.33*△ 7.51±1.49*△ 0.93±0.27*△ F — 26.04 63.07 24.44 P — <0.01 <0.01 <0.01 MS组内 — 10.185 1.409 2.701 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 3 3组大鼠局部肺组织促炎因子相关细胞因子水平比较(x±s)
分组 n IFN-γ/(μg/L) TNF-α/(ng/mL) IL-1β/(pg/mL) IL-6/(pg/mL) MK组 20 52.19±7.26 3.18±1.07 137.42±9.55 184.31±27.68 BPD组 20 64.22±6.33* 7.44±2.46* 177.86±12.31* 238.69±43.15* 对照组 20 44.18±8.39*△ 1.31±0.29*△ 91.42±4.92*△ 137.42±27.66*△ F — 37.41 81.34 420.43 45.42 P — <0.01 <0.01 <0.01 <0.01 MS组内 — 54.390 2.427 88.982 1131.060 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 表 4 3组大鼠局部肺组织抗炎因子相关细胞因子水平比较(x±s)
分组 n IL-4/(pg/mL) IL-10/(ng/mL) IL-13/(ng/L) MK组 20 94.22±16.37 52.16±9.42 42.33±9.16 BPD组 20 115.67±15.23* 77.86±10.49* 63.47±12.29* 对照组 20 72.15±9.88*△ 38.44±5.29*△ 14.31±5.22*△ F — 47.55 105.96 139.16 P — <0.01 <0.01 <0.01 MS组内 — 199.181 75.587 87.399 q检验:与MK组比较*P<0.05;与BPD组比较△P<0.05 -
[1] 任艳丽, 孔祥永, 杜志方, 等.早产儿支气管肺发育不良危险因素前瞻性研究[J].中华实用儿科临床杂志, 2015, 30(10):757. [2] 尹燕丹, 祁媛媛, 洪达, 等.早产儿支气管肺发育不良危险因素及2岁时随访结局[J].中国循证儿科杂志, 2016, 11(2):113. [3] 齐骥, 杨震英.不同时间使用地塞米松对支气管肺发育不良的防治作用[J].中华实用儿科临床杂志, 2015, 30(22):1725. [4] KIM SB, LEE JH, LEE J, et al.The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia[J].Korean J Pediatr, 2015, 58(9):347. [5] DEMIR K, KUMRAL A, DUMAN N, et al.Clarithromycin, montelukast, and pentoxifylline combination treatment ameliorates experimental neonatal hyperoxic lung injury[J].J Matern Fetal Neonatal Med, 2008, 21(6):407. [6] FONSECA LT, SENNA DC, SILVEIRA RC, et al.Association between breast milk and bronchopulmonary dysplasia:a single center observational study[J].Am J Perinatol, 2017, 34(3):264. [7] 张媛柯, 肖群文, 李琪, 等.早产儿支气管肺发育不良发生率及临床危险因素分析[J].中国新生儿科杂志, 2016, 31(3):198. [8] 韩芳, 衣京梅, 石秀玉.小于32周早产儿支气管肺发育不良的危险因素分析[J].解放军医学院学报, 2019, 40(4):321. [9] WILMINK FA, REIJNIERSE J, REISS IKM, et al.Preeclampsiaandrisk ofdeveloping bronchopulmonary dysplasiain verypretermneonates[J].Pregnancy Hypertens, 2019, 15:57. [10] MORROW LA, WAGNER BD, INGRAM DA, et al.Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants[J].Am J Respir Crit Care Med, 2017, 196(3):364. [11] 杨雨晨.早产儿支气管肺发育不良的药物治疗研究进展[J].中国当代儿科杂志, 2018, 20(1):67. [12] HWANG JS, REHAN VK.Recent advances in bronchopulmonary dysplasia:pathophysiology, prevention, and treatment[J].Lung, 2018, 196(2):129. [13] KALIKKOT THEKKEVEEDU R, GUAMAN MC, SHIVANNA B.Bronchopulmonary dysplasia:a review of pathogenesis and pathophysiology[J].Respir Med, 2017, 132:170. [14] VLIEGENTHART RJS, ONLAND W, VAN WASSENAER-LEEMHUIS AG, et al.Restricted ventilation associated with reduced neurodevelopmental impairment in preterm Infants[J].Neonatology, 2017, 112(2):172. [15] SURATE SOLALIGUE DE, RODR GUEZ-CASTILLO JA, AHLBRECHT K, et al.Recent advances in our understanding of the mechanisms of late lung development and bronchopulmonary dysplasia[J].Am J Physiol Lung Cell Mol Physiol, 2017, 313(6):L1101.